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Abstract 
Background: There is lack of ideal and comprehensive economic evaluations of various GDM strategies. The aim 
of this study is to the compare efficacy and cost-effectiveness of five different methods of screening for gestational 
diabetes mellitus (GDM).
Methods: This study is a randomized community non-inferiority trial among 30,000 pregnant women in five different 
geographic regions of Iran, who were randomly assigned to one of the five GDM screening methods. All first trimester 
pregnant women, seeking prenatal care in governmental health care systems, who met our eligibility criteria were 
enrolled. The criteria suggested by the International-Association-of-Diabetes-in-Pregnancy-Study-Group, the most 
intensive approach, were used as reference. We used the non-inferiority approach to compare less intensive strategies 
to the reference one. Along with routine prenatal standard care, all participants were scheduled to have two phases 
of GDM screening in first and second-trimester of pregnancy, based on five different pre-specified protocols. The 
screening protocol included fasting plasma glucose in the first trimester and either a one step or a two-step screening 
method in the second trimester of pregnancy. Pregnant women were classified in three groups based on the results: 
diagnosed with preexisting pre-gestational overt diabetes; gestational diabetes and non-GDM women. Each group 
received packages for standard-care and all participants were followed till delivery; pregnancy outcomes, quality of 
life and cost of health care were recorded in detail using specific standardized questionnaires. Primary outcomes were 
defined as % birth-weight > 90th percentile and primary cesarean section. In addition, we assessed the direct health 
care direct and indirect costs.
Results: This study will enable us to compare the cost effectiveness of different GDM screening protocols and inter-
vention intensity (low versus high).
Conclusion: Results which if needed, will also enable policy makers to optimize the national GMD strategy as a 
resource for enhancing GDM guidelines.
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Background
Gestational diabetes (GDM) defined as hyperglycaemia 
at any time during pregnancy at levels below those that 
occurring in overt diabetes [1]. It is one of the most com-
mon glycemic disorders during pregnancy with occur-
rence of 1–28% of all pregnancies [2–5], along with the 
increased rate of obesity and advanced maternal age is 
rising in prevalence [6]. It is well documented that GDM 
is associated with both short as well as long term higher 
rates of adverse feto-maternal and neonatal outcomes 
[7–11]. From an obstetrical perspective, evidence shows 
that treatment of GDM is effective in reducing the risk 
of many of the important adverse pregnancy outcomes 
[12–14].
Despite the globally accepted importance of screening 
for and treating GDM [13], screening strategies, testing 
methods and even diagnostic optimum glycemic thresh-
olds for GDM remained much controversy for decades 
and no international consensus has been yet established 
[15]. In addition, the former screenings were mainly per-
formed to prevent adverse maternal outcomes compared 
to neonatal complications. Considering this, use of dif-
ferent tests and criteria will impact the prevalence of 
women diagnosed with GDM [5], and could also impact 
poor pregnancy outcomes [16, 17]. There is also much 
controversy about milder forms of GDM. For which, the 
associations of mild GDM with adverse pregnancy out-
comes are not completely understood; there is ongoing 
debate about the benefits of treating mild GDM and the 
impact on health care costs [18–21].
The Hyperglycemia and Adverse Pregnancy Outcomes 
(HAPO) study demonstrated that hyperglycemia at lev-
els below those previous recommended thresholds for 
GDM were associated with adverse maternal and neo-
natal outcomes; hence, the International Association of 
Diabetes in Pregnancy Study Group (IADPSG) intro-
duced new cutoffs for the 2-hour (2 h) oral glucose toler-
ance test (OGTT) in GDM screening and diagnosis [22]. 
Besides, at present, a 3-h 100  g diagnostic test is used 
predominantly in the United States and some other areas, 
whereas much of the world uses the 75 g, 2-h OGTT [5]. 
At present, there is little information regarding the sen-
sitivity and specificity of these test, and hence the rela-
tive clinical effectiveness of the two-steps of the 1-h 50-g 
glucose challenge test (GCT) following 3-h 100  g oral 
glucose tolerance (OGTT) diagnostic test and the one-
step OGTT approaches in the same population. However 
using the IADPSG criteria, two to threefold more women 
qualified for a diagnosis of GDM, potentially adding to 
the costs of care of the already large number of pregnant 
women [23–25].
With both increased prevalence and adopting lower-
ing of the thresholds for diagnosis, the healthcare cost of 
GDM can be expected to rise proportionately. It follows 
that the debate as to whether or not a benefit exists in 
the treatment of GDM assumes even greater importance 
now than in the past. However, since in most countries, 
resources are inevitably scarce, healthcare interventions 
should be evaluated for their impact the on cost as well as 
effectivity on clinical outcomes [26]. Moreover, while not 
recognizing that GDM is associated with adverse preg-
nancy outcomes, over-diagnosis may lead to psychologi-
cal stress, unnecessary treatments and impaired quality 
of life [27–29].
There is lack of ideal and comprehensive economic 
evaluations of various GDM strategies; the majority of 
existing cost-effective analyses are based on decision 
analysis modelling not real data, limited obtained from 
randomized clinical trials that documented controversial 
results [20, 30–38]. In addition most studies have been 
conducted in well-developed high-income countries 
which obviously have more developed healthcare systems 
than low and middle-income countries, where gesta-
tional diabetes has the highest prevalence. According to 
a WHO report, global and local decision-making regard-
ing GDM strategies are challenging due to the lack of 
optimum economic evaluations of various GDM screen-
ing protocols, making it difficult to validated implement 
any national recommendations from a health economic 
perspective [31]. Since resources are unavoidably scarce, 
national health care interventions should be assessed 
for their impact on costs as well as on clinical outcomes; 
the most highly recommended practice is that economic 
evaluation should be an integral part of randomized clin-
ical trials [39]; each population needs to adopt its com-
munity specific guidelines [40].
In this ongoing randomized community-field non-infe-
riority trial, we aimed to compare the cost-effectiveness 
of five different pre-defined GDM screening protocols, 
both one and two step, using different fasting plasma glu-




This study is being performed to provide real data col-
lected from an unbiased population trial for assessment 
of the following hypothesis: (i) the prevalence of GDM 
when using the less intensive GDM screening strategies 
is not more than obtained using the IADPSG criteria. 
(ii) The pre-specified primary outcomes in less inten-
sive GDM screening strategies are not worse than those 
obtained using IADPSG criteria. (iv) The cost of health 
care using less intensive GDM screening strategies is 
not higher than incurred using IADPSG criteria. (v) The 
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numbers needed to treat (NNT) to prevent one primary 
outcome in less intensive strategies are the same as those 
obtained using IADPSG criteria.
The cost of prevention for one primary outcome in 
less intensive strategies is the same as that for IADPSG 
criteria.
According to our research hypothesis, primary out-
comes hence are: percentage of birth weight > 90th 
percentile and primary cesarean section. Secondary 
outcomes are prevalence of neonatal hypoglycemia, 
birth weight < 10th percentile, neonatal admission to the 
intensive care unit, shoulder dystocia and birth trauma 
including fracture of clavicle and brachial plexus injury, 
intrauterine fetal death, preeclampsia and preterm labor, 
neonatal hyperbilirubinemia and hypocalcemia. In addi-
tion, the study will assess the direct health care costs 
including prenatal clinic visits, obstetrician visits, endocri-
nologist visits, dietician visits, blood glucose monitoring 
equipment, laboratory test cost, pharmacotherapy, addi-
tional fetal well-being assessments and hospitalization as 
well as indirect cost of productivity loss and charges to the 
family including traveling, food substitution, mother time 
off paid work, and partner time off work.
Overall study design
This is a randomized community-field trial including 
five GDM screening strategies in a parallel group design. 
Recruitment of the participants took place between Sep-
tember 2016 and January 2019 in 1015 health centers in 
25 selected cities of five provinces of Iran.
All pregnant women < 14  weeks of gestation, who 
received prenatal care from governmental health care sys-
tems were eligible for enrollment, except where the fol-
lowing specific exclusion criteria prevented this: Maternal 
age < 18 years, preexisting diabetes, date of last menstrual 
period not certain, no ultrasound estimation from 6 to 
14  weeks of gestational age available, chronic hyperten-
sion, asthma or currently receiving treatment with oral 
glucocorticoids, β-blockers, oral β-mimetics, Dilantin, or 
antiretroviral agents and past history of bariatric surgery.
All participants received standard prenatal care recom-
mended by the American College of Obstetricians and 
Gynecologists (ACOG) [41]. Moreover, participants were 
scheduled to have two phases of GDM screening in the first 
and second trimesters of pregnancy, based on the pre-spec-
ified protocol for GDM screening, selected for each city.
At each prenatal visit, standardized questionnaires 
were administered to document prenatal as well as other 
data needed for research by trained midwives.
Sample size calculation
Based on previous studies, we assumed that the pri-
mary event rate of macrosomia to be equal to 10% for all 
groups with no difference. To obtain a statistical power 
of 85% with a 1-sided type one error of 0.005 (consider-
ing multiple comparisons) approximately 4700 patients 
per group are needed to show the non-inferiority of more 
intensive compared to lower intensive strategies with a 
marginal difference of 0.03. With a design effect of 0.001 
(for cluster sampling) and loss to follow-up of 11%, sam-
ple size reached to 5200 in each group [42].
In addition, superiority analyses will be designed to 
show that one screening strategy is superior to another 
after non-inferiority has been demonstrated.
Randomization and allocation
Initially all provinces of Iran were categorized to five 
stratum based on their geographic location (North, East, 
West, South, and Center of Iran) and one province in 
each stratum were randomly selected; then, the list of 
the cities located in each province were provided. Since 
the socioeconomic status in the center of provinces may 
differ from other cities, in the second phase, all cities in 
each province were classified in two clusters of center of 
the province and other cities. At the end, four cities were 
randomly selected from the list of other cities in each 
province.
For allocation of protocols, in the cluster of the pro-
vincial centers, five different protocols were randomly 
allocated to each provincial center. Also, in the cluster of 
other cities, four other cities in each province were ran-
domly allocated to the rest of the protocols (Fig. 1). Sam-
ple size for each city was estimated through probability 
proportional to size (PPS), defined by number of live 
births of the cities.
Intervention
Following the approval of this study, the study procedure 
was released as a guideline to all the selected cities. In 
this respect, workshops were conducted in each city to 
introduce the study protocol and train the caregivers and 
study staff accordingly. Dieticians, obstetricians, inter-
nal medics, laboratory technicians and endocrinologists 
in each province were invited to a scientific workshop to 
harmonize and coordinate the follow ups and treatment 
of GDM patients. Scientific teams with specialists and 
executive members conducted visits every 2  months. A 
telegram channel was developed for daily online commu-
nication of scientific members and executive members at 
both provincial and city levels to answer questions and 
solve any problems encountered.
Along with routine standard prenatal care, all pregnant 
women was screened for GDM based on the pre-speci-
fied protocol assigned to each city. In this respect, early 
screening of GDM was conducted in the first trimester 
of pregnancy, using fasting plasma glucose (FPG) from 
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venous sample with the specific threshold based on each 
screening protocol; based on the results of those screen-
ing tests, pregnant women were classified in to three 
groups: (i) diagnosed with preexisting pre-gestational 
overt diabetes; (ii) gestational diabetes and (iii) non-
GDM women. In addition, at 24–28 weeks of gestation, 
those not previously known to have diabetes (overt or 
gestational), were screened again for GDM based on pre-
specified protocol criteria assigned to that city. All study 
participants were followed till delivery and pregnancy 
and neonatal outcomes and health cost were recorded in 
detail. Definitions of various protocols for screening are 
presented in Table 1.
Each group received packages of standard care based 
on their health status. In this respect, non-GDM preg-
nant women received routine standard care recom-
mended by the American College of Obstetricians and 
Gynecologists (ACOG) 2013 [41]. Moreover, pregnant 
diabetic patients received specific prenatal and diabetic 
care, recommended by the American College of Obste-
tricians and Gynecologists (ACOG) 2013 [43] and the 
American Diabetes Association (ADA) 2016 [44].
Summary of management of Gestational Diabetes 
in Pregnancy
After diagnosis of GDM, treatment was initiated with 
medical nutrition therapy, physical activity, and weight 
management and blood glucose monitoring to achieve 
the targets recommended by ADA guideline 2016 [44] 
including fasting, 95 mg/dL, 1-h postprandial, 140 mg/
dL or 2-h postprandial, 120  mg/dL. Medical nutri-
tion therapy for GDM will be individually planed for 
participants by the dietitian. The food plan provides 
enough calorie intake to promote fetal/neonatal and 
maternal health, achieve glycemic goals, and promote 
appropriate gestational weight gain, based on the Die-
tary Reference Intakes (DRI) recommendation includ-
ing a minimum of 175  g carbohydrate, a minimum of 
71 g protein, and 28 g fiber [44].
If women did not achieve glycemic goals within 
2 weeks, pharmacologic therapy will be offered by spe-
cialized physicians including obstetricians, internists 
or endocrinologists at the second level of the health-
care delivery system. Insulin is the first-line agent 
recommended for treatment of GDM. Self-monitor-
ing of blood glucose (SMBG) was used for achieving 
and maintaining therapeutic goals in insulin-treated 
patients. The frequent use of capillary blood glucose 
tests of SMBG was scheduled four times a day, fasting, 
2-h after breakfast, lunch and dinner or if the patients 
had hypoglycemic symptoms for at least 2 weeks. After 
achieving the therapeutic target, SMBG was performed 
two times a day. In addition, if women decline insulin 
therapy, metformin will be offered as an alternative or 
All provinces in Iran 
North of Iran (Golestan province)
West of Iran (Kurdistan province)
Center of Iran (Yazd province) 
East of Iran (South Khorasan province)
South of Iran (Bushehr province)
Stratification according to the 









Other cities in 
each province 
Random allocation
of protocol among 
center of provinces
Golestan province: Gorgan city (E)  
Kurdistan province: Sanandaj city (B) 
Yazd province: Yazd city (C) 
South Khorasan province: Birjand city (D) 
Bushehr province: Bushehr city (A)  
Random allocation of protocol 
among 4 cities in each province 
Golestan Province 
City 1: Gonbad (C) 
City 2: Agh-ghela (D) 
City 3: Torkaman (A) 
City 4: Ali-abad (B) 
Kurdistan Province 
City 1: Saghez (A) 
City 2: Ghorveh (E) 
City 3: Marivan (C) 
City 4: Baneh (D) 
Yazd Province 
City 1: Ardakan (D) 
City 2: Mehriz (B) 
City 3: Meibod (E) 
City 4: Bafgh (A) 
Bushehr Province 
City 1: Dashtestan (C) 
City 2: Dashti (D) 
City 3: Gonaveh (E) 
City 4: Kangan (B) 
South Khorasan Province 
City 1: Ghaen (E) 
City 2: Ferdous (C) 
City 3: Tabas (A) 
City 4: Nehbandan (B) 
Random selection of 
4 cities in each 
provinces 
Fig. 1 Randomization and allocation of study
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adjunct to insulin after clarifying the harms and ben-
efits of metformin therapy for patients [44] (Fig. 2).
Data collection
Data were collected from participants at scheduled time 
points (Table  2) using pre-specified questionnaires and 
clinical and para clinical exams by trained midwives. 
Moreover, data on neonatal mortalities that occurred 
after hospital discharge were collected at 4  weeks post-
partum by telephone and subsequent reviews of medical 
records.
Questionnaires
1. Prenatal questionnaire This comprehensive ques-
tionnaire includes two sections: 1—contains the 
past medical, reproductive, obstetrics, and gyneco-
logical history, completed only at first prenatal visit 
2—focuses on current pregnancy information and 
this part was completed at each prenatal visit during 
pregnancy (Additional file 1: PART 1: Prenatal Care 
Form).
2. Delivery, postpartum and neonatal questionnaire 
This questionnaire contains the details of delivery 
and its methods and any adverse maternal–fetal/neo-
natal outcomes (Additional file 1: PART 2. Childbirth 
and New-born Report Form).
3. Quality of life questionnaire The Iranian version of 
36-item short form health survey questionnaire (SF-
36) [45–48] was used to measure the physical and 
mental components of health-related quality of life. 
The SF-36 included 36 items with 8 subscales; physi-
cal functioning, role limitations due to physical prob-
lems, bodily pain, general health perceptions, vitality, 
social functioning, role limitations due to emotional 
problems and perceived mental health. This ques-
tionnaire was completed monthly for all GDM 
patients since the time of diagnosis. Also, it were 
done for 5% of non-GDM pregnant women visited 
from the first visit for prenatal care (Additional file 1: 
PART 3. 36-Item Short Form Survey Instrument).
4. Cost-effectiveness questionnaire This questionnaire 
included 50 items with three subscales: (i) self-pur-
chased health care, (ii) travel costs for making return 
visit(s) to health care and (iii) time costs of travel-
Table 1 Definitions of various protocols for screening of gestational diabetes mellitus
In the first trimester overt diabetes is defined as FPG ≥ 126 mg/dL
FPG fasting plasma glucose, GCT glucose challenge test, OGTT oral glucose tolerance test
Protocol First trimester Second trimester
Diagnostic criteria for GDM Method for GDM screening Diagnostic threshold of test Diagnostic criteria
A 92 mg/dL < FPG > 126 mg/dL One step with 2-h 75 g OGTT Fasting ≥ 92 mg/dL
1 h ≥ 180 mg/dL
2 h ≥ 153 mg/dL
GDM is defined as any of the given 
plasma glucose values are met or 
exceeded
B 100 mg/dL < FPG > 126 mg/dL One step with 2-h 75 g OGTT Fasting ≥ 92 mg/dL
1 h ≥ 180 mg/dL
2 h ≥ 153 mg/dL
GDM is defined as two or more of the 
given plasma glucose values are 
met or exceeded
C 100 mg/dL < FPG > 126 mg/dL One step with 2-h 75 g OGTT Fasting ≥ 92 mg/dL
1 h ≥ 180 mg/dL
2 h ≥ 153 mg/dL
GDM is defined as any of the given 
plasma glucose values are met or 
exceeded
D 92 mg/dL < FPG > 126 mg/dL Two steps with 50 g GCT—1 h 
following
3-h 100 g OGTT 
50 g GCT: GDM is defined as if two or more of 
the given plasma glucose values in 
100 g OGTT are met or exceeded
  BS-1 h: ≥ 140 mg
100 g OGTT:
  Fasting ≥ 95 mg/dL
  1 h ≥ 180 mg/dL
  2 h ≥ 155 mg/dL
  3 h ≥ 140 mg/dL
E 100 mg/dL < FPG > 126 mg/dL Two steps with 50 g GCT—1 h 
following
3-h 100 g OGTT 
50 g GCT: GDM is defined as if two or more of 
the given plasma glucose values in 
100 g OGTT are met or exceeded
  BS-1 h: ≥ 140 mg
100 g OGTT:
  Fasting ≥ 95 mg/dL
  1 h ≥ 180 mg/dL
  2 h ≥ 155 mg/dL
  3 h ≥ 140 mg/dL
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ling and attending health care center. Effectiveness 
was measured in terms of quality adjusted life years 
(QALYs), using the EQ-5D 3L questionnaire com-
pleted by participants at the follow up time points. 
It includes five questions, each assessing one of 
five dimensions of the health related quality of life 
(Mobility, Self-Care, Usual Activities, Pain/Discom-
fort and Anxiety/Depression). Each of these dimen-
sions has to be answered on a 3-level scale (no prob-
lems, some or moderate problems, and extreme 
problems). The scales are scored from 1 (no problem) 
to 3 (extreme problem) in each question; and finally 
the score digits are placed together to yield a 5-digit 
code for the health status of each patient (Additional 
file 1: PART 4. Cost effectiveness Form).
Maternal anthropometric, clinical, and laboratory 
assessments
Weight was measured to the nearest 100 g using digital 
scales while the participants were minimally clothed, 
without shoes. Height was measured to the nearest 
0.5  cm, in a standing position without shoes, using a 
tape measure, while shoulders were in normal align-
ment. Body mass index (BMI) was calculated as weight 
(kg) divided by height squared  (m2). After a 15-min rest 
in the sitting position, two measurements of systolic and 
diastolic blood pressure (SBP and DBP) were taken on 
the right arm, using a standardized mercury sphygmoma-
nometer (calibrated by the Iranian Institute of Standards 
and Industrial Researches); the mean of the two measure-
ments was considered as the participant’s blood pressure.
Plasma glucose were measured on the day of blood 
collection. A blood sample was drawn between 7:00 
and 9:00 AM from all study participants, after 8 to 10 h 
overnight fasting. For the 75-g OGTT-82.5  g of glucose 
monohydrate solution (equivalent to 75 g anhydrous glu-
cose), for the 50 g glucose challenge test (GCT)-55 g of 
glucose monohydrate solution (equivalent to 50 g anhy-
drous glucose) and for the 100-g OGTT-100 g of glucose 
monohydrate solution (equivalent to 110  g anhydrous 
glucose) were administered orally to subjects and plasma 
glucose was measured, using an enzymatic colorimetric 
method with glucose oxidase; inter- and intra-assay coef-
ficients of variation were less than 2.3%. Analyses were 
performed using Pars Azmon kits (Pars Azmon Inc., Teh-
ran, Iran) using the Selectra 2 auto-analyzer (Vital Scien-
tific, Spankeren, Netherlands).
Neonatal anthropometric, clinical, and laboratory 
assessments
Neonatal anthropometric and clinical measurement 
were measured by trained staff. Birth weight was meas-
ured without diapers using a calibrated digital baby scale 
Initial Assessment
Early GDM* screening by FPG** at gestational age <14 
HealthyGDMOvert DM 




Pharmacologic therapy provided by specialist 
physician
Continued Medical nutrition therapy, physical activity and 
blood glucose monitoring 
GDM screening at gestational age 24-28 w
Glycemic goals not achieved
Blood glucose monitoring after 2 weeks
Fig. 2 Flow chart of screening and management of Gestational Diabetes in Pregnancy. *GDM: gestational diabetes mellitus; **FPG: fasting plasma 
glucose
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(SECA model 334; SECA Corp., Hamburg, Germany) to 
the nearest 1  gr, within an hour after delivery. Recum-
bent length was measured to nearest 0.1 cm from the top 
of the head to the sole of the feet using an infantometer 
(Easy-Glide Bearing Infantometer, Perspective Enter-
prises). Head circumference (HC) was measured at the 
largest occipito-frontal diameter and the measurement 
was rounded to the nearest 0.25 cm. The largest of three 
consecutive measurements was recorded.
In this respect, two measurements were obtained, and 
if results differed by > 10  g for weight and 0.5  cm for 
length or head circumference, a third measurement were 
taken. The average of the two or three measurements was 
used for final analysis.
According to the national Iranian guidelines, all new-
borns were exclusively breastfed early after delivery. 
Infants were either screened for hypoglycemia 1–2  h 
after birth before a feeding based on the presence of 
defined risk factors including maternal GDM/overt DM, 
birth weight > 90th percentile, maternal BMI > 30, birth 
weight < 10th percentile, early preterm birth less than 
34  weeks of gestation, perinatal acidosis, 5-min Apgar 
score of 0–3, failure of breastfeed and sepsis.
In this respect, blood glucose levels were measured 
using heel-stick sampling at 1, 3, 6, 12, and 24  h after 
birth before a feeding. Additional blood glucose measure-
ments were performed in case of hypoglycemia or clinical 
symptoms including sweating, weak or high-pitched cry, 
feeding difficulties, poor sucking, tremors, hypothermia, 
irritability, lethargy/stupor, hypotonia, seizures, apnea, 
grunting or tachypnea or cyanosis. Using point-of-care 
testing, glucose was measured with the glucose oxidase 
method (Pars Azmon Inc., Tehran, Iran).
Cord serum C-peptide sample, as the index of fetal 
β-cell function, was collected at the time of delivery in a 
subsample of 1000 participants with different screening 
protocol. Samples collected were centrifuged for 10 min 
at 3000  rpm, stored at − 80  °C and transferred to cen-
tral laboratory. C-peptide were determined with ELISA 
method (Mercodia AB, Uppsala, Sweden); the inter- and 
intra-assay coefficient of variation were < 2.3% and 1.5%, 
respectively.
The need for other assessments, such as serum biliru-
bin or imaging tests were determined based on clinical 
indications.
Definition of study outcomes
Outcomes of study were defined as follows: Macroso-
mia/large for gestational age (LGA) was defined as 
birth-weight > 4000  g and/or fetal-weight > 90th per-
centile for a given gestational age [49] using ultrasound 
biometry for estimating the fetal-weight and multina-
tional World Health Organization (WHO) fetal growth 
chart for defining the percentile. Primary cesarean sec-
tion was defined as the cesarean deliveries out of all 
births to women who had not had a previous cesarean 
delivery [50]; abortion refers to a termination of a preg-
nancy either natural or induced before the completion 
of 20  weeks of gestation. Polyhydramnios is defined as 
excess accumulation of amniotic fluid with 4-quadrant 
amniotic fluid index (AFI) more than 24  cm or a single 
maximum vertical pocket more than 8  cm [51]. Oligo-
hydramnios refers to decreased amniotic fluid volume 
relative to gestational age with AFI less than 24  cm or 
a single maximum vertical pocket less than 8  cm [52]. 
Intrauterine growth restriction (IUGR)/fetal growth 
restriction was defined as fetal-weight less than the 10th 
percentile for gestational age [53] using ultrasound biom-
etry for estimating the fetal-weight and multinational 
World Health Organization (WHO) fetal growth chart 
for defining the percentile. Small size for gestational age 
(SGA) refers to birth-weight less than the 10th percentile 
for gestational age [53, 54] using gender specific WHO 
weight-for-age chart for defining the percentile. Hypo-
glycemia was defined as plasma glucose concentration 
< 47 mg/dL in the first 48 h after delivery [55, 56]; hyper-
bilirubinemia was determined by value greater than the 
95th percentile for any given point after birth [57]; Ges-
tational hypertension was defined as a systolic pressure 
of ≥ 140  mmHg or a diastolic pressure of ≥ 90  mmHg 
taken on two occasions, at least 4  h apart [58, 59]; 
Preeclampsia was defined as an elevation in blood pres-
sure ≥ 140  mmHg systolic or ≥ 90  mmHg diastolic on 
two occasions at least 4 h apart after 20 weeks of gesta-
tion in a women with a previously normal blood pres-
sure and proteinuria ≥ 300 mg per 24 h urine collection 
or protein/creatinine ratio greater than or equal to 0.3 
or dipstick reading of 1+ and more if other quantitative 
methods were not available. In the absence of proteinu-
ria, new-onset hypertension with the new onset of any 
of the thrombocytopenia, renal insufficiency, impaired 
liver function, pulmonary edema and cerebral or visual 
symptoms [59]; preterm birth was defined as when birth 
occurs between 20 and 37  weeks of pregnancy [60]; 
shoulder dystocia was defined clinically, where provid-
ers are required to provide additional obstetric maneu-
vers when gentle downward traction has failed to affect 
the delivery of the shoulders [61] and birth trauma was 
defined as brachial plexus palsy or clavicular, humeral, or 
skull fracture. Mild GDM is defined as: a fasting glucose 
level of > 92 and < 100  mg per decilitre in 1st trimester 
of pregnancy and only one glucose measurement exceed-
ing from established thresholds for 2-h 75gOGTT as fol-
lows: FPG > 92 mg/dL, 1-h plasma glucose >  180 mg/dL, 
2-h plasma glucose >  53  mg/dL at the 24–28  weeks of 
gestation.
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Data cleaning and missing data
The following minimal data must be available for women 
to be included in the analysis of pregnancy outcomes: 
Completed enrollment forms and questionnaire, com-
pleted results of GDM screening, type of delivery, birth 
weights and clear status of exclusionary criteria.
Missing values will be managed using appropriate 
imputation methods. Outliers will be identified using 
graphical tools including boxplot and/or Model-based 
methods like Chauvenet’s criterion and Dixon’s Q test 
[62, 63].
Data analysis
To illustrate distribution of the data, appropriate descrip-
tive statistics such as measures of central tendency, index 
of dispersion and percentiles will be reported along with 
normality assumption testing through Kolmogorov-
Smirnoff test. Maternal, neonatal and obstetric outcomes 
of the 4 less intensive screening strategies with IADPSG 
criteria will be compared using parametric or non-para-
metric statistical tests, where applicable.
In addition, based on the type of outcome variables, 
Generalized Linear Models (GLMs) with different link 
function such as linear, count or binary will be applied. 
Stepwise method with P-value < 0.2 will be used to 
identify significant confounding variables and estimate 
adjusted measures of interests. Moreover, longitudi-
nal modeling through Generalized Estimating Equation 
(GEE) analysis approach will be conducted and to calcu-
late Number Needed to Treat (NNT), the Linear GLM 
model will be applied as well. Since this is a cluster rand-
omized trial, cluster effect in analysis will be considered.
Cost‑effectiveness analysis (CEA)
A cost-effectiveness analysis, comparing 4 less inten-
sive screening strategies with IADPSG criteria will be 
conducted on an intention-to-treat basis by estimating 
various parameters including Quality-adjusted life years 
(QALYs), incremental cost-effectiveness ratio (ICER), 
and incremental net benefit (INB). To estimate mean cost 
in each treatment group, regression models will be used. 
General linear models (GLM) with appropriate variance 
functions e.g. gamma, Poisson, etc. and link will be used 
to identify the relationship between treatment allocation 
and costs after adjusting for minimization and the appro-
priate prognostic covariates at baseline (e.g. Baseline 
EQ-5D score). To estimate the incremental effect of the 
treatment indicator variable, recycled predictions will be 
used [64].
A sensitivity analysis will be conducted to assess how 
sensitive the cost-effectiveness results are to variation in 
key parameters including cost.
Bayesian and Markov Modeling
Bayesian Cost Effectiveness Modeling (BCEM) will be 
used to overcome the complexity of the relationships 
linking a suitable measure of clinical benefit (e.g. quality-
adjusted life years) and the associated costs. Simplifying 
assumptions, such as normality of the underlying distri-
butions, are usually not granted, particularly for the cost 
variable, which is significantly skewed distributions. In 
addition, individual-level data sets are often character-
ized by the presence of structural zeros in the cost vari-
able [65–67]. Bayesian models will be used to account for 
the presence of excess zeros in a distribution and have 
been applied in the context of cost data (Fig. 3).
Markov model will be used to extrapolate the results 
of the trial beyond the follow up, which will eventually 
provide longer-term cost-effectiveness. Markov decision 
processes (MDPs) are a powerful and appropriate tech-
nique for modelling medical decision. MDPs are most 
useful in classes of problems involving complex, stochas-
tic and dynamic decisions like medical treatment deci-
sions, for which they can find optimal solutions [68]. 
Physicians will always need to make subjective judgments 
about treatment strategies, but mathematical decision 
models can provide insight into the nature of optimal 
choices and guide treatment decisions [69]. Markov 
models can be used to describe various health states in 
a population of interest, and to detect the effects of vari-
ous policies or therapeutic choices. In addition, we will 
apply decision tree analysis and then apply probabilistic 
approach.
All data analysis will be conducted using R (Version 
2.2.2) and TreeAge (Version 13) softwares.
Approval and ethical considerations
This trial has been approved and funded by the National 
Institute for Medical Research Development under 
Grant Agreement No IR.NIMAD.REC.1394.013. Fund-
ing source had no involvement in the study. The proto-
col was approved by the national ethics committee of 
the National Institute for Medical Research Develop-
ment (Approval number: IR.NIMAD.REC.1394.013). 
In addition, the Iranian Ministry of Health and Medical 
Education (MoHME) approved the study protocol and 
pre specified GDM modalities were made available to all 
those provinces as mandatory guidelines. This field trial 
has been registered in Iranian Registry of Clinical Trials 
(Trial Registration: IRCT138707081281N1).
Discussion
At present, there is a lack of international consensus 
about the diagnosis of gestational diabetes. Screening 
strategies, testing methods and even diagnostic opti-
mum glycemic thresholds for GDM remain the subject 
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of considerable debate. Although gestational diabetes 
mellitus is a recognized marker for an increased risk of 
subsequent diabetes, its clinical significance with respect 
to its various definitions and various adverse pregnancy 
outcomes has not been clearly elucidated. Women with 
severe gestational diabetes and highly elevated fasting 
plasma glucose levels apparently are at an increased risk 
for adverse pregnancy outcomes if treatment is not pro-
vided, yet the association of milder forms of gestational 
diabetes with such outcomes remains unclear. Despite 
the HAPO study having provided valuable evidence of 
the association of maternal blood glucose with adverse 
pregnancy outcomes, it is worth noting that HAPO study 
was a purely observational study that conducted in west-
ern countries.
Considering the fact that majority of births annually 
occur in low- and low–middle income countries with 
high prevalence of GDM and limited resources [5], the 
cost-effectivity of this definition needs to be re-evaluated 
in other communities; the present study will hopefully 
provide such information from an eastern Mediterranean 
region. Moreover there is little information compar-
ing the clinical efficacy, utility and feasibility of the two 
step GDM screening test and a 3-h oral glucose tolerance 
test (GTT) and the one step oral glucose tolerance test 
(OGTT) approaches, our study will provide comprehen-
sive data on this comparison in the same population.
According to a WHO report, global and local decision 
making regarding GDM strategies are challenging due 
to the lack of optimum economic evaluations of vari-
ous GDM screening protocols; as a result our study will 
provide the data needed for each community to adopt its 
specific GDM screening guidelines according to the rea-
sonable cost for prevention of the adverse short and long 
term effects of GDM.
The limitations of our study of course should be 
addressed. Since specific questionnaires for evaluation of 
QOL and drug adherence in patients with GDM were not 
available, general questionnaires was used. In addition, 
we did not use the central reference laboratory for all of 
our measurement except C-peptide. Since homogeneity 
of laboratory procedures are essential to the success the 
study, we used standardized procedures in all provinces 
including local training of field center laboratory person-
nel, using a common protocol for measurement of glu-
cose; using of standard equipment and supplies; monthly 
external quality controls for each laboratory. Moreover, 
glycosylated hemoglobin A1c (HbA1c) measurements 
were not available in our study.
Conclusions
Results which if needed, will also enable policy makers 
to optimize the national GMD strategy as a resource for 
enhancing GDM guidelines.
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Fig. 3 A schematic illustration of the process of health economic evaluation
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